Muscarinic Acetylcholine Receptors agonist antibodies

The Company has also employed its propriety technology to identify antibodies to muscarinic acetylcholine receptors, a class of receptors that use G proteins as their signaling mechanism. These GPCR targets possess great therapeutic values for treating psychiatric and neurological disorders such as schizophrenia, dementia, Alzheimer diseases, respectively.

Intensive screening and validating agonist antibodies discovered from its platform technology against the family of muscarinic acetylcholine receptors is still in progress; namely, CHRM1, CHRM2, CHRM3, CHRM4, and CHRM5, all highly valuable and sought after for therapeutics.